Abstract

On the basis of previous toxicity data 4-dimethylaminoazobenzene (DAB) and Sample B of 4-cyanodimethylaniline (CDA) were administered to Alderley Park Wistar derived female rats of 100 and 200 mg/kg (DAB) and 75 and 150 mg/kg (CDA) as a single intraperitoneal injection. The compounds were formulated as a ball-milled suspension in 0.5% w/v aqueous polysorbate 80. Aqueous polysorbate 80 (0.5% w/v), 10 ml/kg, and cyclophosphamide, (CPM), 20 mg/kg, were used as the vehicle (negative) and reference (positive) controls respectively. Samples of bone marrow were examined for the incidence of micronuclei in the polychromatic erythrocytes at 24 h after dosing.The intraperitoneal administration of DAB (100 and 200 mg/kg) and CDA (75 and 150 mg/kg) did not cause an increase in the incidence of micronuclei compared to the vehicle control. CPM caused a significant increase in the incidence of micronuclei.The rat was shown to be a satisfactory experimental animal for the micronucleus test. No evidence was seen to prevent the micronucleus test and cytogenetic analysis from being conducted using bone marrow from the same animal (the ‘cytonucleus test’, Albanese and Watkins, 1983).KeywordsMicronucleus TestSingle Intraperitoneal InjectionVehicle Control GroupBone Marrow SmearCytogenetic DamageThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.